Date receipt dossier
EudraCT number
2017-000106-38
Company / Sponsor
Celgene
Phase
II
Treated organism
Humans
Indication category
Cancer therapy
Disease
B-cell non-hodgkin lymphoma
Therapeutic approach
Immunotherapy
Genetic modification
EGFRt en chimeric antigen receptor against CD19
Method of transfer of nucleic acid of interest
Lentiviral vector
Administered biological material
Autologous Tcells transduced with lentiviral vectors (JCAR017)
Route of administration
Intravenous
Locations in Belgium
UZ Gent
Type of procedure
Contained use only
Current status
Assessed